שווי שוק לרווח Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals leads the field of RNA therapy, having developed the unique INTASYL system to combat melanoma and investing in the modification of immune cells. This price chart on GURU.Markets, where the indicator stands at -0.70, serves as confirmation of the market valuation and is backed by the expertise of a team of genetics and oncology specialists. The scientific community's high level of confidence in targeted intervention methods ensures stable support for the brand's clinical trials.

The P/E ratio measures the market value of a single unit of net income, determining the investment payback period and the market's confidence in future cash flows. By analyzing the P/E based on net income, an investor assesses whether Phio Pharmaceuticals (PHIO) expenditures on retaining leading geneticists and DNA analysis AI platforms are justified by the current capitalization over the long term.